Seventure's Biophytis secures €2m B-round funding

Both Seventure and CM-CIC provided an additional €800,000 for the deal. The two GPs previously invested €3m in the company in June 2009.

Company
Biophytis is a French pharmaceuticals and research company based in Romainville. Founded in 2006 by Stanislas Veillet, it aims to develop drugs derived from nutraceutical active substances used in treatments of metabolic and age-related diseases.

Biophytis's prime projects are the development of Sarcob, a treatment therapy for sarcropenic obesity, and Maculia, which aims to develop a treatment solution for age-related macular degeneration. Both projects have also received grants from the European Regional Development Fund, Fonds Unique Interministeriel, the Essonne and Seine-Saint-Denis departments, the Ile de France region and the city of Paris.

Biophytis is expected to be profitable by 2015. 

People
General manager Isabelle de Cremoux led the investment for Seventure, while CEO Valerie Autier represented Metabrain. Stanislas Veillet is CEO and founder of Biophytis.

Advisers
Equity - Reed Smith, Paris (Legal); Lamy et Associes (Legal). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Early-stage
• Healthcare
• France
• Seventure (SPEF)